SG11201502074YA - Novel inhibitor compounds of phosphodiesterase type 10a - Google Patents

Novel inhibitor compounds of phosphodiesterase type 10a

Info

Publication number
SG11201502074YA
SG11201502074YA SG11201502074YA SG11201502074YA SG11201502074YA SG 11201502074Y A SG11201502074Y A SG 11201502074YA SG 11201502074Y A SG11201502074Y A SG 11201502074YA SG 11201502074Y A SG11201502074Y A SG 11201502074YA SG 11201502074Y A SG11201502074Y A SG 11201502074YA
Authority
SG
Singapore
Prior art keywords
inhibitor compounds
phosphodiesterase type
novel inhibitor
novel
phosphodiesterase
Prior art date
Application number
SG11201502074YA
Other languages
English (en)
Inventor
Hervé Geneste
Michael Ochse
Karla Drescher
Clarissa Jakob
Maricel Torrent
Original Assignee
Abbvie Deutschland
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland, Abbvie Inc filed Critical Abbvie Deutschland
Publication of SG11201502074YA publication Critical patent/SG11201502074YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201502074YA 2012-09-17 2013-09-16 Novel inhibitor compounds of phosphodiesterase type 10a SG11201502074YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702005P 2012-09-17 2012-09-17
US201261702371P 2012-09-18 2012-09-18
PCT/EP2013/069173 WO2014041175A1 (en) 2012-09-17 2013-09-16 Novel inhibitor compounds of phosphodiesterase type 10a

Publications (1)

Publication Number Publication Date
SG11201502074YA true SG11201502074YA (en) 2015-05-28

Family

ID=49226152

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502074YA SG11201502074YA (en) 2012-09-17 2013-09-16 Novel inhibitor compounds of phosphodiesterase type 10a

Country Status (19)

Country Link
US (1) US9388180B2 (cg-RX-API-DMAC7.html)
EP (1) EP2895489B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015528484A (cg-RX-API-DMAC7.html)
KR (1) KR20150056844A (cg-RX-API-DMAC7.html)
CN (1) CN105102461A (cg-RX-API-DMAC7.html)
AR (1) AR092595A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013314244A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015005935A2 (cg-RX-API-DMAC7.html)
CA (1) CA2883910A1 (cg-RX-API-DMAC7.html)
HK (1) HK1206728A1 (cg-RX-API-DMAC7.html)
IL (1) IL237626A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN01900A (cg-RX-API-DMAC7.html)
MX (1) MX2015003419A (cg-RX-API-DMAC7.html)
RU (1) RU2015114331A (cg-RX-API-DMAC7.html)
SG (1) SG11201502074YA (cg-RX-API-DMAC7.html)
TW (1) TW201418264A (cg-RX-API-DMAC7.html)
UY (1) UY35036A (cg-RX-API-DMAC7.html)
WO (1) WO2014041175A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201501458B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015117950A (ru) 2012-10-26 2016-12-20 Ф. Хоффманн-Ля Рош Аг 3,4-дизамещенный 1н-пиразол и 4,5-дизамещенный тиазол в качестве ингибиторов тирозинкиназы syk
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN111592495A (zh) * 2020-07-06 2020-08-28 上海启讯医药科技有限公司 一种2-正丁基-4-氯-5甲酰基咪唑的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US7057042B2 (en) * 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
JP2007508241A (ja) 2003-07-31 2007-04-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン Pde10a阻害剤を用いる糖尿病および関連障害の処置方法
JP2008501776A (ja) 2004-06-07 2008-01-24 ファイザー・プロダクツ・インク 肥満に関連し、かつメタボリックシンドロームに関連する状態の治療としてのホスホジエステラーゼ10の阻害
WO2006028957A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
AR052771A1 (es) * 2004-09-30 2007-04-04 Tibotec Pharm Ltd Pirimidinas biciclicas inhibidoras del vhc
MX2008002207A (es) 2005-08-16 2008-03-27 Memory Pharm Corp Inhibidores de fosfodiesterasa 10.
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007082546A1 (en) 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
BRPI0707223A2 (pt) 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
JP2009527562A (ja) 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ10阻害剤としてのシンノリン誘導体
EP1991530A1 (en) 2006-02-21 2008-11-19 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007096743A1 (en) 2006-02-23 2007-08-30 Pfizer Products Inc. Substituted quinazolines as pde10 inhibitors
CA2643044A1 (en) 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
CA2644850A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
JP2009541481A (ja) 2006-06-26 2009-11-26 ファイザー・プロダクツ・インク Pde10阻害剤としての三環式ヘテロアリール化合物
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
DK2057153T3 (da) 2006-07-10 2012-10-15 Lundbeck & Co As H (3-aryl-piperazin-1-yl)-derivater af 6,7 dialkoxyquinazolin, 6,7- dialkoxyphtalazin og 6,7-dialkoxyisoquinolin
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2009025823A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
WO2009025839A2 (en) 2007-08-22 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
WO2009029214A1 (en) 2007-08-23 2009-03-05 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
RU2010126622A (ru) * 2007-11-30 2012-01-10 УАЙТ ЭлЭлСи (US) Конденсированные с арилом и гетероарилом имидазо[1, 5-а]пиразины в качестве ингибиторов фосфодиэстеразы 10
US20090143392A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
US20090143361A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
AU2008329072A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10
ME02340B (me) 2008-06-10 2017-02-20 Abbvie Inc Triciklična jedinjenja
WO2010054260A1 (en) * 2008-11-07 2010-05-14 Biotie Therapies Gmbh Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2011008597A1 (en) 2009-07-14 2011-01-20 Schering Corporation Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors
US8361962B2 (en) 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK

Also Published As

Publication number Publication date
HK1206728A1 (en) 2016-01-15
CA2883910A1 (en) 2014-03-20
MX2015003419A (es) 2015-09-23
WO2014041175A1 (en) 2014-03-20
AR092595A1 (es) 2015-04-29
RU2015114331A (ru) 2016-11-10
TW201418264A (zh) 2014-05-16
IN2015DN01900A (cg-RX-API-DMAC7.html) 2015-08-07
EP2895489A1 (en) 2015-07-22
IL237626A0 (en) 2015-04-30
BR112015005935A2 (pt) 2017-07-04
US20140107126A1 (en) 2014-04-17
AU2013314244A1 (en) 2015-03-12
EP2895489B1 (en) 2017-10-18
UY35036A (es) 2014-03-31
KR20150056844A (ko) 2015-05-27
CN105102461A (zh) 2015-11-25
AU2013314244A8 (en) 2015-04-30
ZA201501458B (en) 2018-11-28
US9388180B2 (en) 2016-07-12
JP2015528484A (ja) 2015-09-28

Similar Documents

Publication Publication Date Title
IL263262B (en) Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation
SG10201605196PA (en) Novel Inhibitor Compounds Of Phosphodiesterase Type 10A
IL232358A0 (en) Inhibitors of phosphodiesterase type 10a
IL238728A0 (en) Pyrrolopyrimidine compounds as kinase inhibitors
SMT201700596T1 (it) Composti inibitori
ZA201501615B (en) Pyrazolopyrimidine compounds as kinase inhibitors
AP4029A (en) Inhibitors of beta-secretase
IL239153A0 (en) Substitute pyridopyrazine as an inhibitor
IL240593A0 (en) Novel inhibitory compounds of type a10 phosphodiesterase
IL236963A0 (en) beta-secretase inhibitors
IL237626A0 (en) Novel inhibitory compounds of type a10 phosphodiesterase
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201211019D0 (en) Inhibitor compounds
IL238739A0 (en) Novel phosphodiesterase type 10a inhibitory compounds
PT2784068E (pt) Inibidor da fosfodiesterase-4 capaz de evitar os vómitos
IL236946A0 (en) A10-type phosphodiesterase inhibitory compounds
HK1193613A (en) Novel inhibitor compounds of phosphodiesterase type 10a